CTN-0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial

November 30, 2021 /

David Fiellin, MD
Lead Investigator
Yale University School of Medicine
david.fiellin@yale.edu

Investigators will conduct a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6 sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or office-based buprenorphine results in greater treatment retention in approximately 600 patients with opioid use disorder. This trial will also identify implementation barriers, facilitators and acceptability at the patient, provider and health-systems level for office-based methadone with pharmacy administration and/or dispensing.

    Node Involvement

    Lead Node(s):

  • New England Consortium

    • All Participating Nodes:

  • New England Consortium
  • Northstar Node
  • Ohio Valley Node
  • Pacific Northwest Node
  • Western States Node